About the Company
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Adaptimmune Therapeutics PLC
What To Expect From Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) is set to release its Q1 2025 earnings on May 13, 2025. The consensus estimate for Q1 2025 revenue is $6.17 million, and the earnings are expected to ...
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ: ADAP) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis ...
Adaptimmune Reports Growth and Strategic Moves in Q2
Adaptimmune Therapeutics Plc. ( ($ADAP) ) has released its Q2 earnings. Here is a breakdown of the information Adaptimmune Therapeutics Plc.
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement ...
Adaptimmune Faces Nasdaq Delisting Notice Amid Compliance Issues
Adaptimmune Therapeutics ( ($ADAP) ) has shared an announcement. Adaptimmune Therapeutics plc, a company involved in the biotechnology industry, ...
Could The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ownership ...
Every investor in Adaptimmune Therapeutics plc (NASDAQ:ADAP) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see ...
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What ... - Nasdaq
The most recent trading session ended with Adaptimmune Therapeutics PLC (ADAP) standing at $1.20, reflecting a -1.24% shift from the previouse trading day's closing. This move was narrower than ...
Adaptimmune Therapeutics PLC ADR Company & People | ADAP | Barron's
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel ...
Adaptimmune Therapeutics plc (ADAP) Q1 2023 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ: ADAP) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive ...
Similar Companies
Loading the latest forecasts...